The synergys skills
Serge Pampfer, a seasoned embryologist with extensive expertise in immunology, oncology, and stem cell biology, brings a wealth of experience to the company, blending academic research with leadership roles in the life sciences sector. Following a distinguished career as a research master at FNRS and a professor at the University of Louvain, Serge Pampfer transitioned into the startup world. He held pivotal positions such as Chief Scientific Advisor at Arevia GmbH, Chief Operating Advisor at Beta-Cell NV, Chief Scientific Advisor at EureKARE SAS (a specialized investment company), and CEO at WBC SA, an incubator-investor that boasts two successful IPOs and five acquisitions among its accomplishments. His arrival at Lovaltech promises to inject fresh impetus and unrivaled expertise into the life sciences sector. We eagerly anticipate collaborating with Serge Pampfer to propel Lovaltech to new heights of innovation and success.
He joined the Lovaltech team as CEO on November 2, 2023.
A graduate in International General Management from ESSEC Paris, and President of Lovaltech since January 2022, Patrick Barillot has spent his entire career in the pharmaceutical industry as Export Director at Virbac, Commercial Director France at Boehringer-Ingelheim, BU Director at Wyeth (Pfizer), Industrial Commercial Director at Boehringer-Ingelheim and finally Commercial Director at Recipharm.
He left his position in December 2021 to find the start- up Lovaltech and carry out the nasal protein vaccine project resulting from Biomap research University of Tours/INRAE.
Professor of Universities, in anti-Infectious Immunity at the Faculty of Pharmacy of the University of Tours, Isabelle Dimier-Poisson leads the BioMAP team at UMR ISP 1282 University - INRAE, of which she is also the Deputy Director.
Her team, which belongs to the MAbImprove Laboratory of Excellence, develops research themes relating to the design and development of new immunoprophylactic and immunotherapeutic anti-infective strategies. She has internationally recognized expertise in the field of anti-infectious immunology, vaccinology, and the engineering of recombinant vaccine proteins. Her team has published more than 30 articles over the past 5 years and filed 5 patents.
At the origin of the vaccine development project, Isabelle Dimier-Poisson co- founded the start-up Lovaltech in January 2022, for which she will hold the position Scientific Director.
Immunologist specializing in immunotherapies and vaccinology, Mathieu Epardaud joined the BioMAP team of UMR ISP 1282 University – INRAE in 2018 to contribute to the development of anti-cancer immunotherapies and develop strategies for mucosal vaccine platforms.
He has previously contributed to research on (1) preclinical models for studying the immunopathology of tuberculosis in the same UMR, (2) cancer immunotherapy at the Dana Farber Cancer Institute & Harvard Medical School (Boston) and (3) systemic vs mucosal immune response to INRA (Jouy en Josas).
Mathieu Epardaud is involved in the vaccine development project and is one of the founders in January 2022 of the start-up Lovaltech, for which he holds a position of scientific consultant, for the development of the intranasal delivery system.
Omar HASHIM is assistant professor of pharmacology with more than 8 years experience in research and academia, his research interest in the area of immuno-informatics, vaccine design, and immuno-pharmacology.
Moreover, Omar HASHIM has previous commercial experience of more than 12 years in Pharmaceutical companies in midlle east and east Africa markets, being a sales manager at pharma international company and east Africa regional manager of Philadelphia pharmaceuticals. This multidisciplinary profile with academia, research, and commerce indicates a good fit with startup like Lovaltech.
After accomplishing his PhD and working as a Post-doc researcher at Équipe Biomédicaments Anti-Parasitaires - BioMAP UMR Université-INRAE, Omar Hashim joined the team of Lovaltech as a researcher and project manager since February 2024.
University lecturer in Biochemistery at the Faculty of Pharmacy of Tours, Nicolas Aubrey belongs to the BioMAP team of UMR ISP 1282 University - INRAE. He has internationally recognized expertise in the field of protein engineering, in particular antibodies in connection with the MAbImprove laboratory of Excellence. Via its recombinant protein production platform, it was able to design and develop vaccine proteins, the subject of the patent registered by the University of Tours/INRAE and licensed to Lovaltech.
Thus, Nicolas Aubrey co-founded the start-up Lovaltech in January 2022, for which he will have the role of scientific consultant.